Skip to main content
. 2022 Jul 12;130(Suppl 3):32–39. doi: 10.1111/bju.15762

Fig. 1.

Fig. 1

Event‐free survival according to combinations of European Association of Urology (EAU) risk group (low vs high; panels A, B) and prostate‐specific membrane antigen‐positron emission tomography (PSMA‐PET) status (negative/local recurrence vs regional/distant metastasis; panels C, D) in combination with radiotherapy use (panels B, D) or no radiotherapy use (panels A, B) over 36 months of follow‐up.